Clinical trials: completed, sponsored by Bayer
Pain
Self Selection Trial of Naproxen Sodium
A pilot trial to demonstrate that consumers can appropriately select Aleve 24 Hour for their own use based on expected duration of pain greater than 12 hours.
- Trial name
- KEIFER SST (NCT01383486)
- Testing
- Naproxen sodium ER (BAYH6689), Advil
- Where
- 10 sites in United States
- Volunteers
- 253 people, healthy volunteers welcome
- Sponsor
- Bayer
Drug Interactions
Sorafenib Drug Drug Interaction Study in Healthy Male Subjects
To evaluate the effect of levothyroxine on the absorption, distribution, metabolization and elimination of sorafenib and safety in healthy male subjects
- Trial name
- NCT02332031
- Testing
- Sorafenib (Nexavar, BAY43-9006), Levothyroxine
- Where
- Germany
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bayer
Multiple Sclerosis
Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients
To evaluate the evolution of the impact on daily life activities over the first 12 months following the introduction of interferon beta-1b treatment in patients presenting RRMS or patients at high risk of developing Multiple…
- Trial name
- NCT00928967
- Testing
- Interferon beta-1b, (Betaseron BAY86-5046)
- Where
- France
- Volunteers
- 67 people
- Sponsor
- Bayer
Contraception
US Cycle Control and Blood Pressure Study
Birth Control Patch Study
- Trial name
- NCT00920985
- Testing
- Gestodene/EE (FC Patch Low, BAY86-5016), Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A
- Where
- 28 sites in United States
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- Bayer
Osteoporosis, Postmenopausal
Wellnara Post-marketing Surveillance in Japan
This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Wellnara for postmenopausal osteoporosis.
- Trial name
- WELLNARA (NCT01401114)
- Testing
- E2/LNG oral (Wellnara, BAY86-5029)
- Where
- Japan
- Volunteers
- 411 people
- Sponsor
- Bayer
Ovarian Neoplasms
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
Comparison of Nexavar with a placebo as maintenance therapy for patients with advanced Ovarian or primary Peritoneal cancers in complete remission following surgery and one regimen of chemotherapy.
- Trial name
- NCT00791778
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 59 sites in United States, Belgium and 12 more
- Volunteers
- 246 people
- Sponsor
- Bayer
Carcinoma, Hepatocellular, Carcinoma, Renal Cell
Regulatory Post Marketing Surveillance Study on Nexavar®
This surveillance are to identify problems/questions regarding adverse events, factors that are considered to affect on safety and efficacy in the clinical practice of using Nexavar
- Trial name
- NCT01012011
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- South Korea
- Volunteers
- 2,845 people
- Sponsor
- Bayer
Pain
Bioequivalence of Single Dose Extended Release Naproxen Sodium (660 mg) Tablet Versus Naproxen Sodium (220 mg) Tablet Three Times Daily
Bioequivalence trial in healthy adult subjects to determine the bioavailability of 3 different sustained release formulations of naproxen 660 mg relative to the established commercial Aleve 220 mg tablet.
- Trial name
- NCT02549469
- Testing
- Naproxen Sodium ER (BAY117031), 20% HPMC, Naproxen Sodium ER (BAY117031), 30% HPMC, Naproxen Sodium ER (BAY117031), 40% HPMC
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bayer
Wet Macular Degeneration
Non-Persistence/Non-Adherence (NP/NA) in Wet Age-related Macular Degeneration (wAMD) Patients in Germany
In the research study an observation of patients with wet age-related macular degeneration (wet AMD) will be performed. The term observational study indicates that the current course of therapy and the associated circumstances…
- Trial name
- NCT01448538
- Testing
- Anti-VEGF injections
- Where
- Germany
- Volunteers
- 480 people
- Sponsor
- Bayer
Female Contraception
Descriptive, Prospective, Non-interventional Study (NIS) to Describe Mirena and Amenorrhea Related Acceptability in Contraception Indication in Medical Practice
MARILIA is a prospective, non-interventional, multicenter study. The purpose of this study is to describe the acceptability of Amenorrhea in contraception indication of Mirena users during one year follow up in medical practice.
- Trial name
- MARILIA (NCT01833793)
- Testing
- Levonorgestrel IUD (Mirena, BAY86-5028)
- Where
- Algeria
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Bayer
Dysmenorrhea
Comparative Study of BAY86-5300 With a Flexible Extended Regimen for Dysmenorrhea
The is a multi-center, randomized, open-label, active-controlled, parallel-group comparative study (24-week treatment period). The objective of this study is to prove the superiority of BAY 86-5300 with flexible extended regimen…
- Trial name
- NCT01892904
- Testing
- EE20/DRSP(BAY86-5300)
- Where
- 8 sites in Japan
- Volunteers
- 216 people
- Sponsor
- Bayer
Embolism, Atrial Fibrillation and Venous Thrombosis
Bioequivalence Study of Rivaroxaban
The objectives of this study are to establish the bioequivalence between rivaroxaban tablet 15 mg and rivaroxaban granule formulation 15 mg, and to assess the safety and tolerability of rivaroxaban 15 mg in healthy adult male…
- Trial name
- NCT02537457
- Testing
- Rivaroxaban (BAY 59-7939), Rivaroxaban (Xarelto, BAY 59-7939)
- Where
- Japan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bayer
Embolism, Atrial Fibrillation and Venous Thrombosis
Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects
The objectives of this study are to establish the bioequivalence between rivaroxaban tablet 10mg and rivaroxaban granule formulation 10mg, and to assess the safety and tolerability of rivaroxaban 10mg in healthy adult male…
- Trial name
- NCT02537405
- Testing
- Rivaroxaban (BAY 59-7939), Rivaroxaban (Xarelto, BAY 59-7939)
- Where
- Japan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bayer
Renal Artery Obstruction
Gadobutrol Enhanced MRA of the Renal Arteries
Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days.
- Trial name
- GRAMS (NCT01344460)
- Testing
- Gadobutrol (Gadovist, BAY86-4875)
- Where
- 70 sites in United States, Argentina and 11 more
- Volunteers
- 317 people
- Sponsor
- Bayer
Acne Vulgaris
GA YAZ ACNE in China Phase III
The purpose of this study is to evaluate the efficacy and safety of YAZ (drospirenone 3 mg / ethinylestradiol 20 µg) in comparison with placebo in female patients with moderate acne vulgaris over 6 treatment cycles.
- Trial name
- NCT00818519
- Testing
- EE20/Drospirenone (YAZ, BAY86-5300)
- Where
- 7 sites in China
- Volunteers
- 179 people
- Sponsor
- Bayer
Pain, Postoperative
Evaluate Efficacy and Safety of Extended Release (ER) Naproxen Sodium
The objective is to evaluate pain relief of the extended release naproxen sodium 660 mg tablet compared to commercial naproxen sodium 220 mg tablet over 24 hours in patients with postsurgical dental pain.
- Trial name
- VERNE (NCT01389284)
- Testing
- Naproxen Sodium ER (BAYH6689), Naproxen Sodium IR (Aleve, BAYH6689)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Bayer
Pain
Naproxen Sodium Extended-Release Actual Use Study
The purpose of this Study is to assess how subjects will use the investigational product in an uncontrolled, naturalistic environment.
- Trial name
- NCT00751400
- Testing
- Naproxen Sodium ER (BAYH6689)
- Where
- 24 sites in United States
- Volunteers
- 497 people
- Sponsor
- Bayer
Toothache
Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain.
To evaluate the analgesic efficacy of a single, oral dose of a naproxen sodium extended-release tablet, compared to placebo in postsurgical dental pain.
- Trial name
- NCT00720057
- Testing
- Naproxen Sodium ER (BAYH6689)
- Where
- 3 sites in United States
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Bayer
Primary Dysmenorrhea
Effect on Primary Dysmenorrhea
To investigate the potential benefits of a new oral contraceptive (SH T00658ID) on alleviating complaints of dysmenorrhea associated with oral contraceptive use.
- Trial name
- NCT00909857
- Testing
- Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027), Ethinyl estradiol, Levonorgestrel (Miranova)
- Where
- 41 sites in United States, Canada and 4 more
- Volunteers
- 507 people, healthy volunteers welcome
- Sponsor
- Bayer
Drug Interactions
Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women
Physicians might be concerned that Adempas may have a metabolic interaction with oral contraceptives (OC) that could decrease the contraceptive efficacy of the OC.
- Trial name
- NCT02159326
- Testing
- Microgynon, Riociguat (Adempas,BAY63-2521)
- Where
- Germany
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.